RNA — Atrium Therapeutics, Inc. Common Stock
NASDAQ · Healthcare · Biotechnology
$13.80
+$0.03 (+0.22%)
Atrium Therapeutics, Inc. Common Stock (RNA) is a biotechnology company listed on NASDAQ. It is led by Kathleen P. Gallagher, based in 10578 Science Center Drive, San Diego, CA, United States, 92121, with about 511 employees. Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. The company was incorporated in 2025 and is headquartered in San Diego, California.
Latest reported RNA revenue for 2025-09-30 was $12.5M. Net income was -$447.5M. Revenue was up 224.3% from 2025-06-30 to 2025-09-30. RNA currently screens at market cap $217.5M.
Use this RNA page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the RNA quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the RNA SEC filings page. Lician reads the product cache first so this HTML stays unique to Atrium Therapeutics, Inc. Common Stock even when a live quote feed is slow.
About Atrium Therapeutics, Inc. Common Stock
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. The company was incorporated in 2025 and is headquartered in San Diego, California.
RNA Key Statistics
Market Cap
$217.50M
Volume
52,045
Previous Close
$13.62
Day Range
$13.41 – $13.88
P/B Ratio
0.92
EPS
-$2.89
Revenue
$10.90M
Net Income
-$322.30M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+14.0%
Profit Margin
-2957.7%
Employees
511
RNA Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $10.90M | $9.56M | $9.22M | $9.33M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$322.30M | -$212.22M | -$174.00M | -$118.01M |
| EPS (Diluted) | -$2.89 | -$2.91 | -$3.34 | -$2.85 |
Total Assets
$1.56B
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$219.87M
Operating Cash Flow
-$300.87M
Free Cash Flow
$0.00
Atrium Therapeutics, Inc. Common Stock Company Information
- President, CEO & Director
- Kathleen P. Gallagher
- Headquarters
- 10578 Science Center Drive, San Diego, CA, United States, 92121
- Website
- atriumtherapeutics.com
- Phone
- 619 876 0700
- IPO / Founded
- 2013-06-28
- Sector
- Healthcare
- Industry
- Biotechnology